View Item 

Show simple item record

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxis
dc.contributor.authorValentino, L. A.
dc.contributor.authorPipe, S. W.
dc.contributor.authorCollins, P. W.
dc.contributor.authorBlanchette, V. S.
dc.contributor.authorBerntorp, E.
dc.contributor.authorFischer, K.
dc.contributor.authorEwenstein, B. M.
dc.contributor.authorOh, M.
dc.contributor.authorSpotts, G.
dc.date.accessioned2016-09-17T23:53:55Z
dc.date.available2017-10-05T14:33:48Zen
dc.date.issued2016-07
dc.identifier.citationValentino, L. A.; Pipe, S. W.; Collins, P. W.; Blanchette, V. S.; Berntorp, E.; Fischer, K.; Ewenstein, B. M.; Oh, M.; Spotts, G. (2016). "Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxis." Haemophilia (4): 514-520.
dc.identifier.issn1351-8216
dc.identifier.issn1365-2516
dc.identifier.urihttps://hdl.handle.net/2027.42/133561
dc.publisherCambridge University Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherhaemarthrosis
dc.subject.otherhaemophilia
dc.subject.otherjoint bleeding
dc.subject.otherpharmacokinetic‐guided treatment
dc.subject.otherprophylaxis
dc.subject.otherrAHF‐PFM
dc.subject.otherbleeding
dc.titleAssociation of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/133561/1/hae12905_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/133561/2/hae12905.pdf
dc.identifier.doi10.1111/hae.12905
dc.identifier.sourceHaemophilia
dc.identifier.citedreferenceBjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597 – 605.
dc.identifier.citedreferenceSrivastava A, Brewer AK, Mauser‐Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1 – 47.
dc.identifier.citedreferenceNational Hemophilia Foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Available at http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed November 4, 2007.
dc.identifier.citedreferenceAledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391 – 9.
dc.identifier.citedreferenceManco‐Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535 – 44.
dc.identifier.citedreferenceGringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700 – 10.
dc.identifier.citedreferenceValentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359 – 67.
dc.identifier.citedreferenceManco‐Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119 – 27.
dc.identifier.citedreferenceAhlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo‐skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; 77: 3 – 132.
dc.identifier.citedreferenceNilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129 – 35.
dc.identifier.citedreferenceCollins PW, Bjorkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269 – 75.
dc.identifier.citedreferenceAhnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6‐year follow‐up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689 – 97.
dc.identifier.citedreferenceBjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9 ( Suppl. 1 ): 101 – 8; discussion 9‐10.
dc.identifier.citedreferenceden Uijl IE, Mauser Bunschoten EP, Roosendaal G et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011; 17: 849 – 53.
dc.identifier.citedreferenceValentino LA. Considerations in individualizing prophylaxis in patients with hemophilia A. Haemophilia 2014; 20: 607 – 15.
dc.identifier.citedreferenceValentino LA, Reyes CM, Ewenstein B et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia 2014; 20: 630 – 8.
dc.identifier.citedreferenceHilbe JM. Negative Binomila Regression, 2nd edn. UK: Cambridge University Press, 2011.
dc.identifier.citedreferenceBroderick CR, Herbert RD, Latimer J et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012; 308: 1452 – 9.
dc.identifier.citedreferenceLindvall K, Astermark J, Bjorkman S et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012; 18: 855 – 9.
dc.identifier.citedreferenceAronstam A, Kirk PJ, McHardy J et al. Twice weekly prophylactic therapy in haemophilia A. J Clin Pathol 1977; 30: 65 – 7.
dc.identifier.citedreferenceDunn AL, Busch MT, Wyly JB, Sullivan KM, Abshire TC. Arthroscopic synovectomy for hemophilic joint disease in a pediatric population. J Pediatr Orthop 2004; 24: 414 – 26.
dc.identifier.citedreferenceRodriguez‐Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia 2011; 18: 8 – 16.
dc.identifier.citedreferenceKhawaji M, Astermark J, Von Mackensen S, Åkesson K, Berntorp E. Bone density and health‐related quality of life in adult patients with severe haemophilia. Haemophilia 2011; 17: 304 – 11.
dc.identifier.citedreferenceBerntorp E. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Haemophilia 2009; 15: 1219 – 27.
dc.identifier.citedreferenceManco‐Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel‐group trial of routine prophylaxis versus on‐demand treatment With rFVIII‐FS in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119 – 27.
dc.identifier.citedreferenceCollins PW, Blanchette VS, Fischer K et al. Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413 – 20.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hae12905_am.pdf
Size:
241.6KB
Format:
PDF
View/Open
Name:
hae12905.pdf
Size:
191.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.